Tal P - Search Results

1

Targeting mutant p53 for cancer therapy.

Oren M, Tal P, Rotter V. Oren M, et al. Among authors: tal p. Aging (Albany NY). 2016 Jun;8(6):1159-60. doi: 10.18632/aging.100992. Aging (Albany NY). 2016. PMID: 27347904 Free PMC article. No abstract available.

2

Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Madar S, et al. Among authors: tal p. PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013. PLoS One. 2013. PMID: 23630584 Free PMC article.

3

Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Charni M, et al. Among authors: tal p. Cell Death Differ. 2016 Mar;23(3):509-20. doi: 10.1038/cdd.2015.119. Epub 2015 Sep 11. Cell Death Differ. 2016. PMID: 26358154 Free PMC article.

4

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V. Tal P, et al. Oncotarget. 2016 Mar 15;7(11):11817-37. doi: 10.18632/oncotarget.7857. Oncotarget. 2016. PMID: 26943582 Free PMC article.

5

Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.

Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, Rotter V. Shetzer Y, et al. Among authors: tal p. Int J Cancer. 2017 Mar 15;140(6):1364-1369. doi: 10.1002/ijc.30554. Int J Cancer. 2017. PMID: 28008605

6

Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V. Tal P, et al. Oncotarget. 2019 May 7;10(34):3203-3206. doi: 10.18632/oncotarget.26921. eCollection 2019 May 7. Oncotarget. 2019. PMID: 31191814 Free PMC article.

7

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia.

Tuval A, Brilon Y, Azogy H, Moskovitz Y, Leshkowitz D, Salame TM, Minden MD, Tal P, Rotter V, Oren M, Kaushansky N, Shlush LI. Tuval A, et al. Among authors: tal p. Haematologica. 2022 Nov 1;107(11):2548-2561. doi: 10.3324/haematol.2021.280329. Haematologica. 2022. PMID: 35199506 Free PMC article.

8

Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.

Agarwal H, Tal P, Goldfinger N, Chattopadhyay E, Malkin D, Rotter V, Attery A. Agarwal H, et al. Among authors: tal p. Cell Death Differ. 2024 Jul;31(7):855-867. doi: 10.1038/s41418-024-01307-4. Epub 2024 May 14. Cell Death Differ. 2024. PMID: 38745079 Free PMC article.

9

UnReal? Investigating the Sense of Reality and Psychotic Symptoms with Virtual Reality.

Drori G, Bar-Tal P, Stern Y, Zvilichovsky Y, Salomon R. Drori G, et al. Among authors: bar tal p. J Clin Med. 2020 May 28;9(6):1627. doi: 10.3390/jcm9061627. J Clin Med. 2020. PMID: 32481568 Free PMC article.

10

Endovascular treatment of ruptured intracranial aneurysms: factors affecting midterm quality anatomic results: analysis in a prospective, multicenter series of patients (CLARITY).

Pierot L, Cognard C, Anxionnat R, Ricolfi F; CLARITY Investigators. Pierot L, et al. AJNR Am J Neuroradiol. 2012 Sep;33(8):1475-80. doi: 10.3174/ajnr.A3003. Epub 2012 Apr 19. AJNR Am J Neuroradiol. 2012. PMID: 22517279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters